Loss of asthma control after cessation of omalizumab treatment: real life data

INTRODUCTION: Many clinical and observational studies have demonstrated effectiveness of omalizumab (OMA) in the treatment of severe asthma, but the optimal duration of the therapy remains unknown. AIM: The article presents the authors’ clinical experience on OMA cessation in routine practice. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Kupryś-Lipińska, Izabela, Kuna, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952048/
https://www.ncbi.nlm.nih.gov/pubmed/24683390
http://dx.doi.org/10.5114/pdia.2014.40553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952048/
https://www.ncbi.nlm.nih.gov/pubmed/24683390
http://dx.doi.org/10.5114/pdia.2014.40553

Ejemplares similares